---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-059104"
form_type: "8-K"
ticker: null
cik: "0001442836"
company_name: "Mersana Therapeutics, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:25:30.275178+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Mersana Q1 net loss $19.3M ($0.16/shr); XMT-1660 Phase 1 ongoing, XMT-2056 resumed

## Summary
- Net loss of $19.3M ($0.16/shr) vs $56.2M loss ($0.52) in Q1 2023; collaboration revenue $9.2M (up from $7.8M).
- Cash, equivalents and securities $183.1M; expects runway into 2026.
- XMT-1660 Phase 1 dose escalation continues; MTD not yet reached; initial data and expansion expected H2 2024.
- XMT-2056 Phase 1 resumed enrollment after clinical hold lifted; dose escalation planned in 2024.
- R&D expenses fell sharply to $18.7M from $47.3M driven by UpRi discontinuation and restructuring.

## SEC filing metadata
- accession: 0001104659-24-059104
- form_type: 8-K
- cik: 0001442836
- company_name: Mersana Therapeutics, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1442836/000110465924059104/0001104659-24-059104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1442836/000110465924059104/tm2413939d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-059104
- JSON: https://secwatch.observer/filing/0001104659-24-059104.json
- Plain text: https://secwatch.observer/filing/0001104659-24-059104.txt

## Key facts
- Earnings Releases
  Mersana Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $9.2 million, net income $19.3 million net loss, EPS $0.16 per share.
  - Period: first quarter ended March 31, 2024
  - Revenue: $9.2 million
  - Net income: $19.3 million net loss
  - EPS: $0.16 per share
  - Result: reported results
  source text: plan commitments into 2026. ● Net cash used in operating activities for the first quarter of 2024 was $32.7 million. · Collaboration revenue for the first quarter of 2024 was $9.2 million, compared to $7.8 million for the same period in 2023. The year-over-year change was primarily related to the company’s Johnson & Johnson collaboration, including both research
  evidence_url: https://www.sec.gov/Archives/edgar/data/1442836/000110465924059104/0001104659-24-059104-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.